Bli medlem
Bli medlem

Du är här


Weifa ASA : Detailed Stock Exchange Announcement

Weifa ASA - Detailed Stock Exchange Announcement: Weifa's Acquisition of Asan

Oslo, 18 December 2015

Weifa ASA ("Weifa" or the "Company") entered 17 December 2015 into an
agreement with Orkla ASA to acquire Cederroth AS, the company that on closing
of the transaction will own the Norwegian category leading intimate care
brand Asan and its Swedish counterpart Sana (jointly referred to as "Asan"),
for a total consideration of NOK 115 million the "Acquisition").

The Asan portfolio includes products within the mild intimate care soap-, body
and shower-, wet wipes- and fresh categories. The portfolio generated net
sales of NOK 52.7 million in 2014 (Norway and Sweden combined). For the Asan
portfolio, Weifa will target EBITDA margin levels in a range around Weifa's
current level, and the transaction is expected to be accretive on Weifa's net
profit from the first year of operation.

Asan holds a leading position in the Norwegian market for intimate care. The
Asan products have outstanding awareness and loyalty levels among consumers
and Asan is also a leading brand in the general shower category. More than 90
per cent of Asan's sales are generated in the Norwegian grocery trade.

"The Asan portfolio fits perfectly with Weifa's current offering of intimate
care products and strengthens Weifa's position as a leading Consumer health
company. Weifa is about brand management. Value creation in brand portfolios
and sales through a network of wholesalers are our core competencies and our
normal line of business. We are convinced that we can add value to the Asan
portfolio in the same way that we have done with our flagship brands of
Paracet and Ibux
", says Kathrine Gamborg Andreassen, the CEO of Weifa.

Weifa has identified several areas where the Company can utilize its core
competencies to develop the product portfolio further - both through product-
and channel development. These initiatives include leveraging Weifa's network
of wholesalers, improve penetration in the pharmacy channel for the intimate
care category and potential new innovative products based on the current
Weifa portfolio combined with the Asan product line.

The Acquisition is in line with Weifa's expressed strategy of expanding both
organically and by M&A, as well as the ambition to establish a Nordic market

The agreement between Weifa and Orkla is subject to the approval of the
relevant competition authorities, and the Transaction is expected to close in
January 2016.

The Acquisition is financed by a private placement (the "Private Placement")
completed 18 December 2015. The Company raised NOK 118.5 million in gross
proceeds through placing 118.5 million new shares. Reference is made to the
stock exchange notice dated 18 December 2015.

Carnegie acted as financial advisor to Weifa in relation to the Acquisition
and the Private Placement.

About Cederroth AS:

Cederroth AS has been through a carve-in and carve-out process prior to the
transaction so that the entity only consists of business related to the Asan
and Sana brands. For this reason, historical figures for Cederroth AS do not
reflect the assets that Weifa acquire through the Acquisition. For this
reason, Weifa presents the relevant net sales figures for the acquired

Asan financials:

| (NOKm) 2012 2013 2014 |
| Net Sales 51.0 55.0 52.7 |
The Board of Directors prior to the transaction with Weifa consists of
Johannes Arbo Høeg, Stig Ebert Nilssen and Jan Roar Nordby. Note that the
Board of Directors will resign from their positions after the close of the

There are no, nor are there expected to be any, agreements made that would
benefit board members or key personnel at Weifa as a result of the
transaction. The transaction will not include any employees in Cederroth AS.
Weifa will enter into a Transitional Service Agreement and a Contract
Manufacturing Agreement for the Asan and Sana products at market terms with
Cederroth AB.

For further information, please contact:

Kathrine Gamborg Andreassen
+47 951 78 680

Simen Nyberg-Hansen
+47 9820 6355

About Weifa:

Weifa is Norway's leading Consumer health company. Weifa supplies
pharmaceutical products and lifestyle products that address the essential
needs of consumers, customers and professional partners. The Company has a
strong position in Norway and is the market leader in pain relief, with
well-established brands such as Paracet and Ibux, and is also present in
other key areas such as dietary supplements and treatment for colds and
respiratory problems. Weifa is listed on the Oslo Stock Exchange and has its
head office in Oslo. In 2014, the Group had a turnover of approximately NOK
316m in 2014 (after adjusting for the divestment of the B2B business). The
company currently has approximately 30 employees.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Weifa ASA via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.